Premium
Impact of OCT and visual function in multiple sclerosis patients treated with Fingolimod
Author(s) -
PérezVelilla Javier,
José Vicente María,
Vilades Palomar Elisa,
Orduna Hospital Elvira,
Cordón Ciordia Beatriz,
GilArribas Laura,
Ruiz De Gopegui Erika,
Jesús Rodrigo María,
Satué Palacian María,
GarcíaMartín Elena
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.5173
Subject(s) - fingolimod , medicine , visual acuity , ophthalmology , multiple sclerosis , contrast (vision) , optical coherence tomography , retinal , nerve fiber layer , optics , psychiatry , physics
Purpose To evaluate the effect of Fingolimod during one year on the neuro‐retinal structures and visual function in patients with multiple sclerosis (MS). Methods Seventy eight eyes of 78 patients with MS treated with Fingolimod were evaluated every 3 months (for a year) and compared with 32 MS patients treated with Interferon. All subjects underwent visual acuity (VA) test for high and low contrast (100%, 2.5% and 1.25%), contrast sensitivity vision (using the CSV‐1000 and Pelli‐Robson tests), color vision (using the Fansworth and L'Anthony D15 desaturated tests), the thickness of the retinal fiber layer, the ganglion cell layer and the macula by Fourier‐domain optical coherence tomography (OCT). Results In MS patients treated with Fingolimod, a decrease in visual acuity was registered in 100% and 1.25% contrasts (p = 0.009 and p = 0.008respectivelly), as well as a reduction in contrast sensitivity in the Pelli‐Robson test (p < 0.001). Structurally a decrease in the ganglion cell layer (p = 0.008) and an increase in macular thickness (p = 0.006) were found. In MS patients treated with Interferon there is a significant decrease only in ganglion cell layer thickness (p = 0.006), being this decrease higher than in the Fingolimod group (P < 0.006). Conclusions Treatment with Fingolimod causes a significant decrease in visual acuity and contrast sensitivity. It also causes an increase in average central macular thickness compared to the Interferon treatment. It's probable that the increase in central macular thickness is the cause of changes in visual function.